PT  - JOURNAL ARTICLE
AU  - ANDREA SBRANA
AU  - ELISA BIASCO
AU  - FEDERICO PAOLIERI
AU  - ERICA PALESANDRO
AU  - CLAUDIA CASERTA
AU  - ROBERTO IACOVELLI
AU  - BEATRICE DETTI
AU  - DANIELE SANTINI
AU  - ALESSANDRA MOSCA
AU  - FRANCO MORELLI
AU  - GIUSEPPE FORNARINI
AU  - UGO DE GIORGI
AU  - CRISTINA MASINI
AU  - LUCA GALLI
TI  - Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience
AID  - 10.21873/anticanres.12807
DP  - 2018 Aug 01
TA  - Anticancer Research
PG  - 4913--4918
VI  - 38
IP  - 8
4099  - http://ar.iiarjournals.org/content/38/8/4913.short
4100  - http://ar.iiarjournals.org/content/38/8/4913.full
SO  - Anticancer Res2018 Aug 01; 38
AB  - Background/Aim: The specific characteristics of patients who are most likely to benefit from pazopanib therapy are still uncertain. We report on the results of an Italian multicenter, retrospective analysis investigating the factors associated with longer response to first-line pazopanib in patients with metastatic renal cell carcinoma. Patients and Methods: Adult patients were considered if they had received treatment with pazopanib (800 mg/day) for >12 months in the first-line setting. Results: In total, 112 patients were evaluated. Median duration of pazopanib treatment was 22.6 months (IQR 17.8 months). Median PFS was 22.6 months (95%CI= 20.2-25.0). Eighty-three patients (74.1%) had a PFS ≥18 months. Median OS was 32.9 months (95%CI=30.2-35.6). At statistical analysis, only PS score (1+ vs. 0) was significantly associated with PFS (HR=1.76; 95%CI=1.02-3.05; p=0.04). Conclusion: Pazopanib therapy may be suitable for all patients with mRCC, and especially in those with PS 0.